Trial Profile

An International Expanded Access Clinical Programme With ZD1839 (IRESSA) [gefitinib] for Patients With Advanced Non-Small Cell Lung Cancer(NSCLC) and Patients With Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck (H and NC)

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gefitinib (Primary)
Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Expanded access
Sponsors AstraZeneca

15 Dec 2017 Status changed from active, no longer recruiting to completed.
24 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
10 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com